Smith Jeffrey T L
EVP & Chief Medical Officer
Smith Jeffrey T L has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jan 12, 2026.
On the most recent filing, Smith Jeffrey T L is listed as EVP & Chief Medical Officer at Zymeworks Inc. Inside the rolling window, Smith Jeffrey T L reported no open-market purchases and 2 open-market sales totaling $476K in ZYME. The largest disclosed transaction in the window is a sale of 10,538 ZYME shares on Jan 5, 2026, worth $264K.
Companies traded
Other insiders at ZYME
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$476K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Smith Jeffrey T L made?
Smith Jeffrey T L has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Smith Jeffrey T L trade?
Smith Jeffrey T L has filed SEC Form 4 disclosures for 1 company, including ZYME.
When was Smith Jeffrey T L's most recent SEC Form 4 filing?
Smith Jeffrey T L's most recent SEC Form 4 filing on Tracefour is dated Jan 12, 2026.
What is Smith Jeffrey T L's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Smith Jeffrey T L is listed as EVP & Chief Medical Officer.
What is Smith Jeffrey T L's total buy and sell value in the current window?
Inside the rolling retention window, Smith Jeffrey T L bought $0 and sold $476K based on SEC Form 4 filings.
What was Smith Jeffrey T L's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,538 ZYME shares on 2026-01-05, worth $264K, per SEC Form 4 filings.